148 related articles for article (PubMed ID: 22261589)
1. Mucolysis by ascorbic acid and hydrogen peroxide on compact mucin secreted in pseudomyxoma peritonei.
Pillai K; Akhter J; Chua TC; Morris DL
J Surg Res; 2012 May; 174(2):e69-73. PubMed ID: 22261589
[TBL] [Abstract][Full Text] [Related]
2. A formulation for in situ lysis of mucin secreted in pseudomyxoma peritonei.
Pillai K; Akhter J; Chua TC; Morris DL
Int J Cancer; 2014 Jan; 134(2):478-86. PubMed ID: 23843173
[TBL] [Abstract][Full Text] [Related]
3. Potential mucolytic agents for mucinous ascites from pseudomyxoma peritonei.
Pillai K; Akhter J; Chua TC; Morris DL
Invest New Drugs; 2012 Oct; 30(5):2080-6. PubMed ID: 22359216
[TBL] [Abstract][Full Text] [Related]
4. Pseudomyxoma peritonei: does a true mucolytic agent exist? In vitro and in vivo studies.
Shyr YM; Su CH; Wang HC; Lo SS; Lui WY
Am Surg; 1995 Mar; 61(3):265-70. PubMed ID: 7887544
[TBL] [Abstract][Full Text] [Related]
5. MUC2 is a molecular marker for pseudomyxoma peritonei.
O'Connell JT; Hacker CM; Barsky SH
Mod Pathol; 2002 Sep; 15(9):958-72. PubMed ID: 12218214
[TBL] [Abstract][Full Text] [Related]
6. Acidic glycosaminoglycans of abdominal mucin in a case of pseudomyxoma peritonei caused by appendiceal cancer.
Miyashita T; Murata K; Hoshino E; Nishiya H; Ono Y; Akaoka I; Kunii O
Dig Dis Sci; 1999 Nov; 44(11):2231-4. PubMed ID: 10573367
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a novel mucolytic agent on pseudomyxoma peritonei mucin, with potential for treatment through peritoneal catheters.
Akhter J; Pillai K; Chua TC; Alzarin N; Morris DL
Am J Cancer Res; 2014; 4(5):495-507. PubMed ID: 25232491
[TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal hyperthermia in the management of pseudomyxoma peritonei.
Hsu KH; Chou CY; Chang YC
Hepatogastroenterology; 2007; 54(73):47-52. PubMed ID: 17419229
[TBL] [Abstract][Full Text] [Related]
9. In vivo model of pseudomyxoma peritonei for novel candidate drug discovery.
Chua TC; Akther J; Yao P; Morris DL
Anticancer Res; 2009 Oct; 29(10):4051-5. PubMed ID: 19846950
[TBL] [Abstract][Full Text] [Related]
10. Physical and chemical characteristics of mucin secreted by pseudomyxoma peritonei (PMP).
Pillai K; Akhter J; Mekkawy A; Chua TC; Morris DL
Int J Med Sci; 2017; 14(1):18-28. PubMed ID: 28138305
[No Abstract] [Full Text] [Related]
11. [Pseudomyxoma peritonei; a rare tumour that can be treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy].
Smeenk RM; Verwaal VJ; Zoetmulder FA
Ned Tijdschr Geneeskd; 2007 Feb; 151(7):418-23. PubMed ID: 17343142
[TBL] [Abstract][Full Text] [Related]
12. Histopathologic analysis in 46 patients with pseudomyxoma peritonei syndrome: failure versus success with a second-look operation.
Yan H; Pestieau SR; Shmookler BM; Sugarbaker PH
Mod Pathol; 2001 Mar; 14(3):164-71. PubMed ID: 11266521
[TBL] [Abstract][Full Text] [Related]
13. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
McKenney JK; Soslow RA; Longacre TA
Am J Surg Pathol; 2008 May; 32(5):645-55. PubMed ID: 18344868
[TBL] [Abstract][Full Text] [Related]
14. [A case of pseudomyxoma peritonei with a pancreatic cancer treated by the intraperitoneal administration of cisplatinum].
Mitsuhashi T; Murata N; Sobajima J; Okada N; Suzuki T; Ishida H; Hashimoto D; Miura I; Itoyama S
Gan To Kagaku Ryoho; 2001 Oct; 28(11):1670-3. PubMed ID: 11708005
[TBL] [Abstract][Full Text] [Related]
15. [Two cases of pseudomyxoma peritonei that responded to intraperitoneal administrations of a combined CDDP, 5-FU and MMC therapy].
Sasaki A; Terashima M; Okamoto K; Ikeda K; Takagane A; Takiyama I; Kuboi M; Sasaki N; Saito K
Gan To Kagaku Ryoho; 1996 Sep; 23(11):1571-4. PubMed ID: 8854808
[TBL] [Abstract][Full Text] [Related]
16. Pseudomyxoma peritonei: possible prevention of mucinous ascites by peritoneal lavage.
Piver MS; Lele SB; Patsner B
Obstet Gynecol; 1984 Sep; 64(3 Suppl):95S-96S. PubMed ID: 6472756
[TBL] [Abstract][Full Text] [Related]
17. Pseudomyxoma peritonei: a clinicopathologic analysis and follow-up of 21 patients.
Varona JF; Guerra JM; Salamanca J; Colina F; Lopez G; Morales M
Hepatogastroenterology; 2005; 52(63):812-6. PubMed ID: 15966210
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of pseudomyxoma peritonei is developing].
Lepistö A; Osterlund P; Järvinen HJ
Duodecim; 2010; 126(14):1693-9. PubMed ID: 20804088
[TBL] [Abstract][Full Text] [Related]
19. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
[TBL] [Abstract][Full Text] [Related]
20. [Pseudomyxoma peritonei].
Andreassen G
Tidsskr Nor Laegeforen; 1995 Sep; 115(22):2783. PubMed ID: 7570495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
